The repair and regeneration of bone defects remains a fundamental challenge in orthopedics, dental implantation, and maxillofacial surgery. When patients face significant bone loss, traditional autografts often prove inadequate due to donor site complications, limited bone availability, and postoperative pain. In such cases, safe and effective allograft or xenograft alternatives become crucial. Among various bone substitute materials, InterOss® inorganic cancellous bone granules have emerged as a trusted solution for bone tissue regeneration, distinguished by their natural origin, high purity, and unique microstructure.

InterOss®'s primary advantage lies in its rigorous sourcing and purification process. The product is derived exclusively from Australian bovine bone—a deliberate choice reflecting Australia's stringent animal disease control systems that ensure cattle health and safety while mitigating risks like bovine spongiform encephalopathy (BSE). This foundation eliminates biological safety concerns at the source.

The material undergoes multi-stage purification to completely remove organic components (including proteins and fats) while preserving inorganic mineral content—primarily hydroxyapatite. This process enhances biological inertness, reduces immunogenicity, and crucially, achieves chemical composition and crystal structure nearly identical to human bone minerals. This natural similarity ensures exceptional osteoconductive properties.

InterOss®'s sophisticated porous architecture significantly contributes to its effectiveness by creating an optimal environment for bone cell growth, vascularization, and nutrient transport:

• High surface area: The purification process creates extensive internal surfaces that provide abundant attachment points for bone cells, facilitating proliferation, differentiation, and tissue formation.
• Macropores (>100μm): These larger channels enable migration of marrow stromal cells and vascular endothelial cells, serving as "highways" for vascular ingrowth that accelerates defect site vascularization.
• Micropores (<10μm): Smaller pores allow permeation of bodily fluids, growth factors, and nutrients, sustaining cellular activity while influencing material degradation rates—a balance that can be adjusted for optimal regeneration.
• Mesopores (10-100μm): Intermediate pores bridge structural scales, further optimizing permeability and cell migration.

This interconnected, multi-scale pore system forms an ideal scaffold that guides new bone formation while promoting integration with existing tissue for functional reconstruction.

As an inorganic material, InterOss® demonstrates controlled resorption rates that provide durable mechanical support—preventing premature collapse while allowing gradual replacement by new bone. The material's porosity also enables clinicians to select products with specific degradation characteristics tailored to individual cases.

Supplied as 0.25-1.0mm gamma-irradiated sterile granules, InterOss® offers clinical convenience and adaptability for defect filling. The product meets stringent international standards with certifications including U.S. FDA, European CE, and Korean KFDA approvals—reflecting its safety, efficacy, and quality control. U.S. regulations restrict distribution to licensed dental professionals, underscoring its medical device classification.

Proper storage in dry, ventilated environments at 15-25°C (59-77°F) and strict adherence to aseptic techniques during handling are essential to maintain sterility and performance.

Through its biocompatibility, optimized architecture, and clinical reliability, InterOss® represents a significant advancement in bone regeneration—combining natural origins with engineered precision to address complex reconstructive challenges.